Societe Generale’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Societe Generale’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$26.6M	Buy	+492,161	New	+$27M	0.19%	91

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Societe Generale's XBI Position: Q2 2016 in Review

Societe Generale opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2016: 492,161 shares worth $26.6M. The stake represents 0.19% of the portfolio and ranks #91 among its holdings.

201 funds tracked by Wall St. Rank hold XBI as of Q2 2016.

Societe Generale held 492,161 shares of State Street SPDR S&P Biotech ETF worth $26.6M as of Q2 2016.
State Street SPDR S&P Biotech ETF was a new Societe Generale position in Q2 2016.
State Street SPDR S&P Biotech ETF made up 0.19% of Societe Generale's portfolio in Q2 2016, its #91 holding.
201 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.